Basecamp Research

"Design novel protein sequences and biological systems that can transform therapeutic R&D" [1]

Where it wins

• Access to the world's largest ethically sourced biological database, containing 100 times more advanced biological systems than public pharma databases [1].
• AI models that improve performance as they see more diversity and context, allowing design of complex biological systems beyond known biology [1].
• Proven ability to accelerate biocatalyst discovery for chemical synthesis, reducing energy use and waste compared to traditional catalysis [2].
• Ethical compliance with the Nagoya Protocol, ensuring royalties are passed to conservation organizations where genetic resources are sourced [2].

Credibility: Tech.eu funding report [1]; Johnson Matthey partnership press release [2].

• Sells AI-driven biological design services and licensed enzymes to pharma and chemical industries [2][1].
• Scales by expanding its foundational dataset of biological information, which improves AI model performance [1].
• Unit of value is novel protein sequences and biological systems designed for specific therapeutic or chemical applications [1].
• Margin sits in the proprietary AI models and the unique, ethically sourced biodiversity data [2][1].

• Johnson Matthey: Competes in biocatalysis but partners with Basecamp for AI-driven biodiversity mapping [2].
• Public pharma databases: Basecamp's dataset is 100 times larger and more advanced [1].
• Traditional protein engineering firms: Basecamp's AI offers faster, more diverse design capabilities [2][1].
• Other AI biotech companies: Basecamp's unique ethical data and global partnerships provide a distinct advantage [1].

Differentiators: Scale and ethics of biological data, proven AI performance improvements with more data, and strong industry partnerships.

• Time-consuming search for suitable enzymes in organic synthesis, requiring multiple rounds of protein engineering [2].
• High energy use and waste in pharmaceutical and agrochemical industries from traditional catalysis [2].
• Data gap in the biotech industry limiting AI's ability to design complex biological systems [1].
• Need for sustainable, bio-based catalysts to meet industry sustainability goals [2].

Basecamp's wedge is its proprietary, ethically sourced biological data, which creates a moat against competitors relying on public databases. The main risk at scale is maintaining ethical compliance and data quality as the dataset expands. The opportunity lies in expanding into new therapeutic areas and chemical applications through its AI platform. The next signal to watch is the commercial success of enzymes licensed to partners like Johnson Matthey and the progress of the Broad Institute collaboration.

Expand marketing efforts to highlight the ethical sourcing and Nagoya Protocol compliance to attract sustainability-focused partners. Interconnection: This would strengthen customer relationships and differentiate from competitors. Develop a self-service platform for smaller biotech firms to access AI design tools, lowering the barrier to entry. Interconnection: This would diversify the customer base and increase revenue streams. Invest in more public case studies demonstrating the impact of licensed enzymes on sustainability goals. Interconnection: This would enhance credibility and attract more partners in the chemical industry.